Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Amanda N. Seddon et al.|Blood|2020Cited by 318
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Jennifer A. Woyach et al.|New England Journal of Medicine|2023Cited by 213
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael Wang, Nirav N. Shah, Wojciech Jurczak et al.|Journal of Clinical Oncology|2023Cited by 106
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Christopher P. Fox et al.|Clinical Cancer Research|2019Cited by 90